- 专利标题： Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same
-
申请号： US16760539申请日： 2018-10-29
-
公开(公告)号： US11377504B2公开(公告)日： 2022-07-05
- 发明人: Yasuhiro Matsumura , Masahiro Yasunaga , Shinji Saijo , Ryo Tsumura
- 申请人： National Cancer Center Japan , RIN Institute Inc.
- 申请人地址： JP Chuo-ku; JP Chuo-ku
- 专利权人： National Cancer Center Japan,RIN Institute Inc.
- 当前专利权人： National Cancer Center Japan,RIN Institute Inc.
- 当前专利权人地址： JP Chuo-ku; JP Chuo-ku
- 代理机构： Oblon, McClelland, Maier & Neustadt, L.L.P.
- 优先权： JPJP2017-208907 20171030
- 国际申请： PCT/JP2018/040017 WO 20181029
- 国际公布： WO2019/087994 WO 20190509
- 主分类号： C07K16/36
- IPC分类号： C07K16/36 ; A61K47/68 ; A61P35/00 ; G01N33/68 ; A61K39/00
摘要：
The present invention provides an antibody beneficial for treatment of a solid tumor, an antibody-drug conjugate thereof, and an anticancer agent comprising these. The present invention provides, for example, an antibody that binds to tissue factor or an antigen-binding fragment thereof, wherein the antibody has a dissociation rate constant kd of 5×10−4 s−1 or more and an association rate constant Ka of 1×104 M−1 s−1 or more.
公开/授权文献
信息查询
